Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis

Vaccine

Volumn 32, Issue 43, 2014, Pages 5696-5702

  von Sonnenburg, Frank ^a   Perona, Pamela ^a   Darsow, Ulf ^b   Ring, Johannes ^b   von Krempelhuber, Alfred ^c,e   Vollmar, Jens ^c,e   Roesch, Siegfried ^c   Baedeker, Nicole ^c   Kollaritsch, Herwig ^d   Chaplin, Paul ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Bavarian Nordic GmbH   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e GLAXOSMITHKLINE   (Germany)

Author keywords

Atopic dermatitis; Eczema vaccinatum; MVA; Smallpox; Vaccination

Indexed keywords

MODIFIED VACCINIA ANKARA VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ALLERGIC RHINITIS; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ATOPIC DERMATITIS; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSESTHESIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE BURNING; INJECTION SITE NODULE; MALE; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; SEROCONVERSION; SWELLING; URTICARIA; VACCINATION; VERTIGO; ANTIBODY PRODUCTION; BLOOD; CELLULAR IMMUNITY; CHEMICALLY INDUCED; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; CONTRAINDICATIONS; ECZEMA; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; SMALLPOX; VACCINIA VIRUS; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DERMATITIS, ATOPIC; ECZEMA; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; SMALLPOX; SMALLPOX VACCINE; VACCINATION; VACCINIA VIRUS; YOUNG ADULT;

EID: 84908403648     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.022     Document Type: Article

References (32)

1. Lane J.M., Ruben F.L., Abrutyn E., Millar J.D. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 1970, 212(April (3)):441-444.
2. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and its eradication 1988, WHO, Geneva.
3. Engler R.J., Kenner J., Leung D.Y. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002, 110(September (3)):357-365.
4. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003, 37(July (2)):251-271.
5. Howell M.D., Gallo R.L., Boguniewicz M., Jones J.F., Wong C., Streib J.E., et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006, 24(March (3)):341-348.
6. Leung D.Y., Bieber T. Atopic dermatitis. Lancet 2003, 361(January (9352)):151-160.
7. Lane J.M., Millar J.D. Risks of smallpox vaccination complications in the United States. Am J Epidemiol 1971, 93(April (4)):238-240.
8. Shirasawa K., Akai K., Kawaguchi Y., Maeda S., Nagahara S., Toyoda H., et al. Widespread eczema vaccinatum acquired by contacts. A report of an autopsy case. Acta Pathol Jpn 1979, 29(May (3)):435-455.
9. Scott J.E., Elkhal A., Freyschmidt E.J., MacArthur D.H., McDonald D., Howell M.D., et al. Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation. J Allergy Clin Immunol 2007, 120(December (6)):1382-1388.
10. Rotz L.D., Dotson D.A., Damon I.K., Becher J.A. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001, 50(June (RR-10)):1-25.
11. Neff J.M., Lane J.M., Fulginiti V.A., Henderson D.A. Contact vaccinia - transmission of vaccinia from smallpox vaccination. JAMA 2002, 288(October (15)):1901-1905.
12. Kemper A.R., Davis M.M., Freed G.L. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002, 5(March (2)):84-90.
13. National Jewish Health ADVN atopic dermatitis and vaccinia network 2010.
14. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl.). Dtsch Med Wochenschr 1974, 99(November (47)):2386-2392.
15. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl.). Zentralbl Bakteriol [B] 1978, 167(December (5-6)):375-390.
16. Mayr A., Hochstein-Mintzel V., Stickl H. Passage history, properties, and use of attenuated vaccinia virus strain MVA. Infection 1975, 3(1):6-14.
17. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006, 24(March (12)):2065-2070.
18. Frey S.E., Newman F.K., Kennedy J.S., Sobek V., Ennis F.A., Hill H., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007, 25(December (51)):8562-8573.
19. von Krempelhuber A., Vollmar J., Pokorny R., Rapp P., Wulff N., Petzold B., et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010, 28(February (5)):1209-1216.
20. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005, 79(June (12)):7845-7851.
21. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(March (6979)):182-185.
22. Samuelsson C., Hausmann J., Lauterbach H., Schmidt M., Akira S., Wagner H., et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008, 118(May (5)):1776-1784.
23. Earl P.L., Americo J.L., Wyatt L.S., Espenshade O., Bassler J., Gong K., et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 2008, 105(August (31)):10889-10894.
24. Damon I.K., Davidson W.B., Hughes C.M., Olson V.A., Smith S.K., Holman R.C., et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009, 90(August):1962-1966.
25. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004, 43(May (9)):1503-1510.
26. Kunz B., Oranje A.P., Labreze L., Stalder J.F., Ring J., Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997, 195(1):10-19.
27. Vollmar J. Clinical experience with a smallpox vaccine in populations with contraindications for vaccination with Dryax. International conference of emerging infectious diseases 2006.
28. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(June (9580)):2161-2170.
29. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8(January (1)):13-24.
30. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002, 346(April (17)):1265-1274.
31. Bull M., Lee D., Stucky J., Chiu Y.L., Rubin A., Horton H., et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007, 322(April (1-2)):57-69.
32. Greenberg R.N., Overton E.T., Haas D.W., Frank I., Goldman M., von Krempelhuber A., et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 2013, 207(March (5)):749-758.